INS and Hypoglycemia: Insulin degludec has an onset of action within 1–2 h, lacks a distinct peak, and maintains glucose-lowering effects for up to 42 h, reducing the risk of hypoglycemia by 25% compared to insulin glargine and allowing greater dosing flexibility with timing variations of up to 8 hours (71).